Nov 10, 2026
Inhibikase Posts $20.5 Million Third-Quarter Net Loss as PAH Trial Advances
Inhibikase Therapeutics (IKT) reported a net loss of $20.5 million for the third quarter ended September 30, 2026, with $193.3 million in cash, cash equivalents, and marketable securities. The company's Phase 3 IMPROVE-PAH study of IKT-001 is progressing, having secured regulatory approvals in 28 countries and activated 79 clinical sites. Research and development expenses increased to $15.0 million, and the company sold 25 million common shares for $50 million in gross proceeds in July.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Neutral
Nov 2, 2026
Inhibikase Targets Investors Ahead of PAH Drug Development
Inhibikase Therapeutics Inc. (Nasdaq: IKT) is scheduled to meet with institutional investors at healthcare conferences in London and Florida during November and December 2026. The company is advancing the development of IKT-001, a once-daily oral antiproliferative drug candidate for pulmonary arterial hypertension (PAH). CEO Mark Iwicki will participate in a fireside discussion at the Jefferies Global Healthcare Conference and hold one-on-one meetings at the Evercore Healthcare Conference to engage with investors regarding the clinical development of IKT-001.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish